Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Part of paid clinical trials in Fort Myers, Florida.
- Sponsor
- SCRI Development Innovations, LLC
- Study ID
- NCT00294931
- Phase
- PHASE2
- Status
- Completed
Conditions
- Carcinoma, Small Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan — DRUG
- carboplatin — DRUG
- bevacizumab — DRUG
Study Details
This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.
Key Dates
- Start date
- Feb 28, 2006
- Status verified
- Jan 2009
- Primary completion
- May 31, 2007
- Completion
- Jan 31, 2009
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
median time to progression
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | - |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | - |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | - |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37023 | - |
Find similar trials in Fort Myers, FL
Related Studies
- Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerPHASE2 · Recruiting · Pfizer · Duarte, California